The Journal of family practice
-
Skin and soft tissue infections (SSTI) and community-acquired pneumonia (CAP) are major public health problems that are commonly encountered in the primary care setting. Establishing the severity of disease is an important step in the diagnosis of SSTI and CAP, because this can affect decisions about optimal management, including level of care. ⋯ Improved utilization of oral outpatient antibiotic treatments can also minimize the risk of serious adverse effects or nosocomial infections, leading to better patient outcomes. As these infections are mostly treated in outpatient settings, primary care clinicians are best suited to implement changes such as use of oral antibiotics, where appropriate, to reduce hospitalization, with its associated costs and risks to the patient.
-
Given the growing prevalence of antibiotic resistance globally, there is an urgent need for new therapy options that are effective and well tolerated for treatment of common infections such as bacterial skin infections and pneumonia. Here, we summarize the findings of 3 phase 3 clinical trials of omadacycline, a novel tetracycline-derived aminomethylcycline, in patients with acute bacterial skin and skin structure infections (ABSSSI; OASIS-1 [NCT02378480] and OASIS-2 [NCT02877927]) or community-acquired bacterial pneumonia (CABP; OPTIC [NCT02531438]). The primary endpoint in all studies was early clinical response (early response) at 2 to 3 days (skin studies) or 3 to 5 days (pneumonia study) after the first dose. ⋯ No differences were observed in subgroup analyses, and high rates of clinical response were seen for all treatments against common pathogens. The most frequent adverse event reported was nausea, which was mostly associated with the loading dose in the oral-only regimen in OASIS-2. Overall, omadacycline was well tolerated and showed high rates of clinical response in patients with skin infections and pneumonia, including in those with comorbidities.